FDARxBench: Benchmarking Regulatory and Clinical Reasoning on FDA Generic Drug Assessment
arXiv cs.AI / 3/23/2026
📰 NewsIdeas & Deep AnalysisModels & Research
Key Points
- A new expert-curated benchmark, FDARxBench, evaluates document-grounded question-answering using FDA drug label documents to assess regulatory and clinical reasoning.
- It was developed with FDA regulatory assessors and uses a multi-stage pipeline to generate high-quality, expert-curated QA examples spanning factual, multi-hop, and refusal tasks.
- The evaluation framework tests both open-book and closed-book reasoning and uncovers substantial gaps in factual grounding, long-context retrieval, and safe refusal behavior of current models.
- While motivated by FDA generic drug assessment needs, FDARxBench also provides a foundation for regulatory-grade evaluation of drug-label comprehension and LLM behavior.
Related Articles
How CVE-2026-25253 exposed every OpenClaw user to RCE — and how to fix it in one command
Dev.to
Does Synthetic Data Generation of LLMs Help Clinical Text Mining?
Dev.to
What CVE-2026-25253 Taught Me About Building Safe AI Assistants
Dev.to
Day 52: Building vs Shipping — Why We Had 711 Commits and 0 Users
Dev.to
The Dawn of the Local AI Era: From iPhone 17 Pro to the Future of NVIDIA RTX
Dev.to